The effect of fucoidan, heparin and cyanogen bromide-fibrinogen on the activation of human glutamic-plasminogen by tissue plasminogen activator.
Earlier studies on the stimulatory effect of fucoidan, heparin, and cyanogen bromide (CNBr)-fibrinogen digest on the in-vitro activation of glutamic type plasminogen by tissue plasminogen activator, which were performed using subphysiologic ionic strengths of buffers, gave inconsistent results because of the variation in the ionic strengths of the buffers used. Studies were therefore conducted on the effect of these cofactors using 0.05 mol/l Tris buffer containing a physiologic concentration of sodium chloride. The double reciprocal plots of the activation of glutamic type plasminogen by tissue plasminogen activator in the presence of fucoidan and 6-aminohexanoic acid (6-AH) or heparin and 6-AH showed a four- to six-fold increase in K(cat), while the K(m) remained unchanged. On the other hand, there was greater than six-fold lowering of K(m) from 0.213 to 0.035 micromol/l in the presence of CNBr-fibrinogen, while K(cat) was only slightly increased. The ratios of the initial rate of plasmin generation in the presence or absence of the cofactors were plotted against the inverse of the volume fraction of glutamic type plasminogen or of tissue plasminogen activator after serial dilution. The results suggested that the enhancements by fucoidan and 6-AH or CNBr-fibrinogen were due to their interactions directed towards glutamic type plasminogen, while for heparin and 6-AH, the interaction was directed towards tissue plasminogen activator. Circular dichroism studies in the near ultraviolet range (250-308 nm) showed that 6-AH enhanced the circular dichroism spectra of glutamic type plasminogen around certain chromophores, while fucoidan and heparin had no effect, suggesting that the enhancement by the cofactors may be related to the favorable conformational changes of glutamic type plasminogen by 6-AH.
Bell
Jason
J
Chemistry Department, Prairie View A University, Prairie View, TX 77446, USA.
Duhon
Shalisha
S
Doctor
Vasant M
VM
D015119:Aminocaproic Acid / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology; D002021:Buffers; D004789:Enzyme Activation / Q000187:drug effects; D005340:Fibrinogen / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D010958:Plasminogen / Q000378:metabolism*; D011134:Polysaccharides / Q000494:pharmacology*; D012965:Sodium Chloride; D010959:Tissue Plasminogen Activator / Q000378:metabolism*
D000925:Anticoagulants; D002021:Buffers; D011134:Polysaccharides; D012965:Sodium Chloride; D005340:Fibrinogen; D010958:Plasminogen; D006493:Heparin; C007789:fucoidan; D010959:Tissue Plasminogen Activator; D015119:Aminocaproic Acid